| abstract |
The present invention has the general formula (Ig) (wherein, R 1 is, independently, H, alkyl, cycloalkyl, hydroxyalkyl, represents haloalkyl, haloalkyloxy, aryl or heteroaryl; R 2 is independently , —NR 3 R 5 , (Formula II); R 3 is independently H, COR 6 , CO 2 R 6 , SOR 6 , SO 2 R 6 , SO 3 R 6 , alkyl, cycloalkyl, Represents alkoxy, —NH 2 , alkylamine, —NR 7 COR 6 , halogen, —OH, —SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl; R 5 is independently H, COR 6, CO 2 R 6, SOR 6, SO 2 R 6, SO 3 R 6, alkyl, cycloalkyl, alkoxy, -NH 2, Rukiruamin, -NR 7 COR 6, represents halogen, -OH, -SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl; R 6 is, independently, H, alkyl, cycloalkyl, -NH 2 represents an alkylamine, aryl or heteroaryl; R 7 independently represents H, alkyl, cycloalkyl, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, aryl or heteroaryl; p is Q is 0 or 1; X is CO or SO 2 ), or a pharmaceutically acceptable salt thereof with an acid or base, or a pharmaceutically acceptable pro Related to drugs or stereoisomers. |